Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating conversation that dives deeper into emerging questions surrounding the use of NITs in a landscape which features drug approval.
Surfing NASH returns to its regular podcast schedule with a review of the recently concluded Paris NASH meeting. Presenters and KOLs Scott Friedman and Laurent Castera join Jörn Schattenberg, Louise Campbell and Roger Green for a fascinating session that focuses largely on important and emerging questions surrounding the use of NITs in a landscape which features drug approval. This opening conversation highlights the different presentations delivered by the guests followed by discussion around the liver as a regenerative organ and the use and limitations of NITs.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment features ideas around how health care systems can improve and important lessons learned from the COVID pandemic.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes. This segment introduces three important questions that the group aims to answer throughout the wider episode.
Last week, the podcast revisited an episode from Season 1 that maintains its relevance now more than ever. In a fascinating conversation with Stephen Harrison, Peter Traber (Chief Medical Officer at Selecta Biosciences), Louise Campbell and Roger Green, you will learn about how passionate providers (nurses, physicians and allied health professionals) can motivate patient lifestyle changes.
What do liver nursing KOLs see as the largest, most important changes they can hope for 2-3 years from now?
As efficacious NASH drugs near the market, what steps can we take to ensure that patients receive treatment early enough in the course of therapy?
How does the misalignment of liver patients’ needs and nursing availability limit chances to intervene early in the course of Fatty Liver disease?
Nursing KOLs discuss the extensive backgrounds and diverse skill sets they bring to the challenge of educating Fatty Liver patients early in disease progression.
